Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer

Lancet Oncology

Volumn 2, Issue 6, 2001, Pages 335-342

  Jassem, Jacek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS;

EID: 0035383257     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00387-9     Document Type: Review

References (62)

1. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J Clin. 49:1999;33-64.
2. Ihde D.C., Minna J.D. Non-small cell lung cancer I. Biology, diagnosis and staging. Curr Probl Cancer. 15:1991;61-104.
3. Coy P., Kennelly G.M. The role of curative radiotherapy in the treatment of lung cancer. Cancer. 45:1980;698-702.
4. Lee R.E. Radiotherapy of bronchogenic carcinoma. Semin Oncol. 1:1974;245-252.
5. Johnson D.H., Einhorn L.H., Bartolucci A., et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med. 113:1990;33-38.
6. Dillman R.O., Berry C., Ryan K.P., et al. Recent outcomes for patients with carcinoma of the lung. Cancer Invest. 9:1991;9-17.
7. Hoffman P.C., Maurer A.M., Vokes E.E. Lung cancerl. Lancet. 355:2000;479-485.
8. Roswit R., Patno M.E., Rapp P., et al. The survival of patients with inoperable lung cancer: a large scale randomised study of radiation therapy versus placebo. Am J Radiol. 90:1968;688-697.
9. van Houtte P., Klastersky J., Renaud A., et al. Induction chemotherapy with cisplatin, etoposide and vindesine before radiation chemotherapy for nonsmall-cell lung cancer. A randomised study. Antibiot Chemother. 41:1988;131-137.
10. Mattson K., Holsti L.P., Holsti P., et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol. 24:1988;477-482.
11. Morton R.F., Jett J.R., McGinnis W.L., et al. Thoracic radiation therapy alone compared with chemoradiotherapy for locally unresectable non-small cell carcinoma of the lung. Ann Intern Med. 115:1991;681-686.
12. Trovo M.G., Minatel E., Veronesi A., et al. Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study. Cancer. 65:1990;400-404.
13. Soresi E., Clerici M., Grilli R., et al. A randomized clinical trial comparing radiation therapy plus cis-dichlorodiammine platinum in the treatment of locally advanced non-small cell lung cancer. Semin Oncol. 15:1988;20-25.
14. Gregor A., Macbeth F.R., Paul J., et al. Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: a randomized trial. J Natl Cancer Inst. 85:1993;997-999.
15. Planting A., Helle P., Drings P., et al. A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. Ann Oncol. 7:1996;139-144.
16. Crino L., Latini P., Meacci M., et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small cell lung cancer. Ann Oncol. 4:1993;847-851.
17. Wolf M., Hans K., Becker H., et al. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol. 21:1994;42-47.
18. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
19. Le Lorier J., Grégorie G., Benhaddad A., et al. Discrepancies between meta-analyses and subsequent large randomised, controlled trials. N Engl J Med. 337:1997;536-542.
20. Dickersin K. The existence of publication bias and risk factors for its occurrence. J Am Med Assoc. 263:1990;1385-1389.
21. Dillman R.O., Seagren S.L., Herndon J., et al. A randomized trial of induction chemotherapy plus high-dose radiotherapy vs. radiotherapy alone in stage III non-small cell lung cancer. N Engl J Med. 329:1990;940-945.
22. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 88:1996;1210-1214.
23. Donaldson N., Dillman R.O., Wallace J., Ortiz-Hurlado A. Sequential re-analysis of a phase-III clinical trial in non-small cell lung cancer. Eur Respir J. 15:2000;821-827.
24. Sause W., Scott C., Taylor S., et al. RTOG 88-08, ECOG 4588, preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst. 87:1995;198-205.
25. Sause W., Kolesar P., Taylor S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest. 117:2000;358-364.
26. Komaki R., Scott C.B., Sause T., et al. Induction cisplatin/vinblastine and irradiation vs irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Rad Oncol Biol Phys. 39:1997;537-544.
27. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung cancer: first analysis of a randomised trial in 353 patients. J Natl Cancer Inst. 83:1991;417-423.
28. Le Chevalier T., Arriagada R., Tarayre M., et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma [letter]. J Natl Cancer Inst. 8:1992;58.
29. Cullen M.H., Billingham L.J., Woodrofee C.M., et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 17:1999;3188-3194.
30. Brodin O., Nou E., Mercke C., et al. Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. Eur J Cancer. 32A:1996;1890-1893.
31. Kubota K., Furuse K., Kawahara M., et al. Role of radiotherapy in combined modality treatment of locally advanced non-small cell lung cancer. J Clin Oncol. 12:1994;1547-1552.
32. Sculier J.P., Paesmans M., Lafitte J.J., et al. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small cell lung cancer responding to induction chemotherapy. Ann Oncol. 10:1999;295-303.
33. Jassem J., Begg A.C., Stewart F.A., et al. Combined chemotherapy and radiotherapy. Peckham M., Pinedo H.M., Veronesi U. Oxford Textbook of Oncology. 1995;811-822 Oxford University Press, Oxford.
34. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1999;1137-1143.
35. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1999;1144-1153.
36. Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys. 13:1987;403-426.
37. Canetta R., Franks C., Smaldone L., et al. Clinical status of carboplatin. Oncology. 1:1987;61-69.
38. Pinedo H.M., Karim A.B., van Vliet W.H., et al. Daily cisdichlorodiammineplatinum (II) as a radio-enhancer: a preliminary toxicity report. J Cancer Res Clin Oncol. 105:1983;79-82.
39. Van Harskamp G., Boven E., Vermorken J.B., et al. Phase II trials of combined radiotherapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 13:1987;1735-1738.
40. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 326:1992;524-530.
41. Trovo N.G., Minotel E., Fravelun G., et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 24:1992;11-16.
42. Blanke C., Ansari R., Montravadi R., et al. A phase III trial of thoracic irradiation with and without concomitant cisplatin for locally advanced unresectable non-small cell lung cancer: A Hoosier Oncology Group study. J Clin Oncol. 13:1995;1425-1429.
43. Bonner J.A., McGinnis W.L., Stella P., et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma. Results of a North Central Cancer Treatment Group phase III study. Cancer. 82:1998;1037-1048.
44. Ball D., Bishop J., Smith J., et al. A randomized phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 52:1999;129-136.
45. Jeremic B., Shibamoto Y., Acimovic L., et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 13:1995;452-458.
46. Jeremic B., Jevremovic S., Mijatovic L., et al. Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non-small cell lung cancer. Cancer. 71:1993;3732-3736.
47. Jeremic B., Shibamoto Y., Acimovic L., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 14:1996;1065-1070.
48. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent vs sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer: five-year median follow-up results. J Clin Oncol. 17:1999;2692-2699.
49. Furuse K., Hosoe S., Masuda N., et al. Impact of tumor controlon survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT)and chemotherapy (CT). Proc Am Soc Clin Oncol. 19:2000;484a. (abstr).
50. Morsac B., Scott C., Curran W., et al. A quality-adjusted time without symptoms and toxicity (QTWIST) analysis of Radiotherapy Oncology Group (RTOG). Proc Am Soc Clin Oncol. 20:2001;313a. (abstr).
51. Clamon G., Herndon J., Eaton W., et al. A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Cancer Invest. 12:1994;273-282.
52. Clamon G., Herndon J., Cooper R., et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol. 17:1999;4-11.
53. Choy H., Browne M.J. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol. 22:1995;70-74.
54. Mason K.A., Hunter N.R., Milas M., et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 3:1997;2431-2438.
55. Koukourakis M.I., Bahlitzanakis N., Froudarakis M., et al. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br J Cancer. 80:1999;1792-1796.
56. Choy H., Safran H., Akerley W., et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res. 4:1998;1931-1936.
57. Milas L., Fuji T., Hunter N., et al. Enhancement of tumor-radioresponse in vivo by gemcitabine. Cancer Res. 59:1999;107-114.
58. Vokes E.E., Gregor A., Turrisi A.T. Gemcitabine and radiation therapy for non small cell lung cancer. Semin Oncol. 25:1998;66-69.
59. Gralla R., Harper P., Johnson S., et al. Vinorelbine (navelbine) in the treatment of non-small cell lung cancer: recent developments in combination chemotherapy and radiotherapy. Ann Oncol. 10:1999;S47-S51.
60. Vokes E.E., Leopold K.A., Herndon J.E., et al. CALGB Study 9431:a randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT)and concomitant chemoradiotherapy (XRT) for unresectablestage III non-small cell lung cancer (NSCLC). Lung Cancer. 29:2000;49.
61. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.
62. Saunders M., Dische S., Barrett A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet. 350:1997;161-165.